Literature DB >> 26500736

Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation.

Daniel H Miller1, Jennifer L Peterson1, Steven J Buskirk1, Laura A Vallow1, Randy Ta2, Richard Joseph3, Murli Krishna4, Stephen J Ko1, Katherine S Tzou1.   

Abstract

Hidradenocarcinoma is a rare aggressive form of cutaneous adnexal skin carcinoma originating from the sweat gland. Due to its low incidence, prognostic and treatment strategies are still being explored both for primary and advanced disease. This tumor most often presents as either solid or cystic appearing subcutaneous nodules, which may be associated with pruritus or ulceration. To date the mainstay of treatment for local disease has been surgical excision; however, the paucity of historical data available has shown that these tumors often behave aggressively with high rates of local recurrence, metastasis, and poor overall outcomes. There are few case reports describing the utility of radiation therapy in the treatment of hidradenocarcinoma. Herein, we present a case of metastatic apocrine hidradenocarcinoma in a 32-year-old Caucasian male. The patient initially underwent excisional biopsy which confirmed the diagnosis of poorly differentiated, highly infiltrative, apocrine hidradenocarcinoma. He received systemic chemotherapy for metastatic disease, followed by radiation therapy to areas of grossly palpable adenopathy. Prior to radiation therapy the patient had an enlarged hypermetabolic conglomerate of lymph nodes in the right axilla, and borderline enlarged low activity nodes within the left axilla. He received 3 cycles of chemotherapy followed by tamoxifen and radiation therapy (50.4 Gy in 28 fractions) to areas of progressive disease in the bilateral axilla, lower neck, and axillary skin. Following treatment, the patient had complete resolution of skin nodules and improvement of his pruritus. While the role of radiation therapy in the treatment of hidradenocarcinoma has not been well established, this case report demonstrated the potential benefit of external beam radiotherapy in the management of this rare disease.

Entities:  

Keywords:  Hidradenocarcinoma; dose regimen; radiotherapy

Year:  2015        PMID: 26500736      PMCID: PMC4600998          DOI: 10.4081/rt.2015.6082

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


  12 in total

1.  Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors.

Authors:  Steve R Martinez; Keira L Barr; Robert J Canter
Journal:  Arch Dermatol       Date:  2011-09

2.  Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.

Authors:  Kaoutar Tlemcani; Douglas Levine; Richard V Smith; Margaret Brandwein-Gensler; David A Staffenberg; Madhur K Garg; Keivan Shifteh; Missak Haigentz
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

Review 3.  Hidradenomas and a hidradenocarcinoma of the scalp managed using Mohs micrographic surgery and a multidisciplinary approach: case reports and review of the literature.

Authors:  Regina Yavel; Molly Hinshaw; Venkat Rao; Gregory K Hartig; Paul M Harari; Daniel Stewart; Stephen N Snow
Journal:  Dermatol Surg       Date:  2009-02       Impact factor: 3.398

Review 4.  Hidradenocarcinomas: a brief review and future directions.

Authors:  Steven Gauerke; James J Driscoll
Journal:  Arch Pathol Lab Med       Date:  2010-05       Impact factor: 5.534

5.  Metastatic hidradenocarcinoma with demonstration of Her-2/neu gene amplification by fluorescence in situ hybridization: potential treatment implications.

Authors:  Jason W Nash; Terry L Barrett; Merrill Kies; Merrick I Ross; Nour Sneige; A Hafeez Diwan; Alexander J F Lazar
Journal:  J Cutan Pathol       Date:  2007-01       Impact factor: 1.587

6.  Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, and optimal therapy for a rare neoplasm.

Authors:  Kerry L Hollowell; Steven C Agle; Emmanuel E Zervos; Timothy L Fitzgerald
Journal:  J Surg Oncol       Date:  2011-09-12       Impact factor: 3.454

Review 7.  Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment.

Authors:  R S Chamberlain; K Huber; J C White; R Travaglino-Parda
Journal:  Am J Clin Oncol       Date:  1999-04       Impact factor: 2.339

8.  Nodular hidradenoma and hidradenocarcinoma. A 10-year review.

Authors:  E Hernández-Pérez; R Cestoni-Parducci
Journal:  J Am Acad Dermatol       Date:  1985-01       Impact factor: 11.527

9.  Apocrine hidradenocarcinoma of the scalp: a classification conundrum.

Authors:  Marc Cohen; David S Cassarino; Hubert B Shih; Elliot Abemayor; Maie St John
Journal:  Head Neck Pathol       Date:  2008-12-05

10.  Radiotherapy on hidradenocarcinoma.

Authors:  Issam Lalya; Khalid Hadadi; El Mehdi Tazi; Ilham Lalya; Amine Bazine; Khalid Andaloussy; Mohamed Elmarjany; Hassan Sifat; Khalid Hassouni; Tayeb Kebdani; Hamid Mansouri; Noureddine Benjaafar; Brahim Khalil Elgueddari
Journal:  N Am J Med Sci       Date:  2011-01
View more
  7 in total

1.  Breast carcinoma or sweat gland carcinoma? A report of two cases and a comparison with the literature

Authors:  Mauricio Luján; Gabriel Varela; Diego Morán
Journal:  Biomedica       Date:  2021-09-22       Impact factor: 0.935

Review 2.  Current Treatment Options for Cutaneous Adnexal Malignancies.

Authors:  Hiroyuki Goto
Journal:  Curr Treat Options Oncol       Date:  2022-03-26

3.  [Atypical course of an apocrine sweat gland carcinoma of the axilla : A very rare malignant tumor and its interdisciplinary treatment].

Authors:  U Wauer; D Lorenz; R Sellei; E Zoga; S Braun
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

4.  Malignant Hidradenocarcinoma of the Axilla.

Authors:  Evan P Johnson; Jonathan Keyes; Vania Zayat; Jeremy Caudill
Journal:  Cureus       Date:  2020-02-24

5.  Hidradenocarcinoma.

Authors:  Andrey Amorim de Lima; Monica Santos; Patricia Motta de Morais; Carlos Alberto Chirano Rodrigues
Journal:  An Bras Dermatol       Date:  2021-02-05       Impact factor: 1.896

6.  Eccrine Carcinoma With an Unknown Primary: Managing Occult Cancer Through Multidisciplinary Tumor Board Collaboration.

Authors:  Melissa Mariano; Chinmay Jani; Prateek Khanna; Dipesh Patel; John Perry; Bhargavi Yalamarti; Anthony Abner
Journal:  Cureus       Date:  2022-03-15

Review 7.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.